autosomal recessive spinocerebellar ataxia 24

Autosomal recessive spinocerebellar ataxia 24 (SCAR24) is a rare neurologic disorder characterized by abnormal movements, particularly affecting the cerebellum and its connections. The clinical features of SCAR24 include:

• Cataract
• Horizontal nystagmus
• Cerebellar atrophy
• Dysarthria (speech disorder)
• Gait ataxia (difficulty walking)
• Limb ataxia (difficulty with coordinated movements of the limbs)
• Spastic gait

These symptoms are a result of the disruption in visual fixation and saccadic intrusions, which can lead to delayed psychomotor development and intellectual disability in some cases.

According to [1], SCAR24 is one of the many autosomal recessive spinocerebellar ataxias that affect the cerebellum and/or its connections. The disease is caused by a mutation in the UBA5 gene, which leads to the degeneration of the cerebellum and its connections.

It's worth noting that SCAR24 is a rare disorder, with an estimated prevalence of 1-2.5/100,000 [9]. The exact cause and mechanism of the disease are still not fully understood, but research continues to uncover more information about this complex condition.

References: [1] - Context result 3 [4] - Context result 4 [8] - Context result 8 [9] - Context result 9

Autosomal recessive spinocerebellar ataxias are a group of rare genetic disorders that affect the cerebellum, leading to progressive loss of coordination and balance. The signs and symptoms of these conditions can vary depending on the specific type, but here are some common features:

*

Autosomal recessive spinocerebellar ataxia 24 (ARSCA24) is a rare genetic disorder that affects the cerebellum and other parts of the nervous system. Diagnostic tests for ARSCA24 are crucial in confirming the diagnosis, which can be challenging due to its rarity.

Diagnostic Tests:

• Molecular Genetics Tests: Targeted variant analysis is one of the diagnostic tests available for ARSCA24 (Context 3). This test examines specific genetic variants associated with the condition.
• DNA Testing: A DNA test for Friedreich ataxia, an autosomal recessive disorder, can be ordered separately (Context 4). Although this test is primarily used to diagnose Friedreich's ataxia, it may also be relevant in diagnosing ARSCA24 due to the overlap between the two conditions.
• Genetic Testing: Genetic tests for known spinocerebellar ataxia (SCA) genes are increasingly available (Context 7). These tests can help identify genetic mutations associated with ARSCA24.

Other Diagnostic Tests:

• Imaging Studies: Magnetic resonance imaging (MRI) of the brain is often used to rule out other conditions that may cause similar symptoms (Context 15).
• Blood Tests: Blood tests, such as those measuring ceruloplasmin and serum copper levels, may be necessary in patients with progressive ataxia of unknown origin (Context 2).

Important Considerations:

• Genetic Counseling: Genetic counseling is essential for individuals and families affected by ARSCA24. This can help them understand the condition, its inheritance pattern, and the implications for family members.
• Multidisciplinary Approach: A multidisciplinary approach involving neurologists, geneticists, and other specialists is often necessary to diagnose and manage ARSCA24.

In summary, diagnostic tests for autosomal recessive spinocerebellar ataxia 24 include molecular genetics tests, DNA testing, genetic testing, imaging studies, and blood tests. A comprehensive evaluation by a multidisciplinary team of healthcare professionals is crucial in confirming the diagnosis and developing an effective treatment plan.

Based on the provided context, it appears that there are limited treatment options available for autosomal recessive spinocerebellar ataxia (ARSCA). Here's a summary of what I found:

• There are currently no FDA-approved treatments for ARSCA [2][3].
• Medications may be available to treat symptoms that complicate an ARSCA illness, but there is no specific treatment for the condition itself [2].
• Some studies have suggested potential therapies such as medications (e.g., riluzole), botulinum toxin, physical and occupational therapy, but these are not specifically mentioned in the context of ARSCA [1].

It's essential to note that autosomal recessive spinocerebellar ataxia is a rare condition, and more research is needed to understand its treatment options. If you're looking for information on drug treatments, it might be helpful to consult with a healthcare professional or search for more recent studies.

References: [1] SD Ghanekar (2022) - Potential therapies such as medications, botulinum toxin, physical and occupational therapy may be considered. [2] SL Perlman (2020) - There are currently no FDA-approved treatments for ataxia. Medications are available to treat symptoms that may complicate an ataxic illness. [3] SL Perlman (2020) - There are currently no FDA-approved treatments for ataxia. Medications are available to treat symptoms that may complicate an ataxic illness.

Autosomal recessive spinocerebellar ataxias (SCARs) are a group of rare neurodegenerative disorders that primarily affect the cerebellum and its connections. When considering the differential diagnosis for SCAR, several conditions should be taken into account.

• Friedreich's Ataxia: This is the most common form of autosomal recessive ataxia, characterized by progressive damage to the nervous system, leading to symptoms such as gait and limb ataxia, dysarthria, lower limb areflexia, and heart disease.
• Ataxia-Telangiectasia (AT): This is a rare genetic disorder that affects the nervous system, immune system, and other bodily systems. It is characterized by progressive cerebellar ataxia, telangiectasias (dilated blood vessels), immunodeficiency, and an increased risk of cancer.
• Ataxia with Oculomotor Apraxia Type 1 (AOA1): This is a rare autosomal recessive disorder that affects the nervous system, characterized by progressive cerebellar ataxia, oculomotor apraxia (difficulty moving the eyes), and other symptoms.
• Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): This is a rare autosomal recessive disorder that affects the nervous system, characterized by progressive spasticity and ataxia.

These conditions should be considered in the differential diagnosis for SCAR, as they share similar symptoms and can be challenging to distinguish from one another. A comprehensive diagnostic evaluation, including molecular analysis of the pathogenic gene, is essential to confirm the correct diagnosis.

References:

• [1] by F Palau · 2006 · Cited by 253 — Patients with AVED show clinical signs similar to those in Friedreich ataxia, including gait and limb ataxia, dysarthria, lower limb areflexia, ...
• [8] FA is the most common form of recessive ataxia, followed by ataxia-telangiectasia, ataxia with oculomotor apraxia type 1, and autosomal-recessive spastic ataxia of Charlevoix-Saguenay.
• [14] Other ataxia conditions are becoming increasingly recognized, such as the autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS, SACS gene) and spinocerebellar ataxia autosomal recessive 8 (SCAR8, SYNE1 gene).